Stock analysts at Canaccord Genuity raised their price target on shares of Sarepta Therapeutic (NASDAQ:SRPT) from $25.00 to $27.00 in a report issued on Tuesday, AnalystRatings.Net reports. The firm currently has a “hold” rating on the stock. Canaccord Genuity’s target price indicates a potential downside of 10.86% from the company’s current price. The analysts noted that the move was a valuation call.
A number of other analysts have also recently weighed in on SRPT. Analysts at JMP Securities downgraded shares of Sarepta Therapeutic from an “outperform” rating to a “market perform” rating in a research note on Monday, January 27th. They now have a $25.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Needham & Company upgraded shares of Sarepta Therapeutic from a “hold” rating to a “buy” rating in a research note on Tuesday, January 21st. They now have a $36.00 price target on the stock. Finally, analysts at Citigroup Inc. downgraded shares of Sarepta Therapeutic from a “neutral” rating to a “sell” rating in a research note on Monday, January 6th. They now have a $13.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $28.08.
Sarepta Therapeutic (NASDAQ:SRPT) traded down 2.28% on Tuesday, hitting $29.60. The stock had a trading volume of 322,399 shares. Sarepta Therapeutic has a 52-week low of $12.12 and a 52-week high of $55.61. The stock has a 50-day moving average of $26.62 and a 200-day moving average of $30.05. The company’s market cap is $1.113 billion.
Sarepta Therapeutic (NASDAQ:SRPT) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.77) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.69) by $0.08. The company had revenue of $2.60 million for the quarter, compared to the consensus estimate of $4.53 million. During the same quarter in the prior year, the company posted ($2.36) earnings per share. The company’s quarterly revenue was down 64.4% on a year-over-year basis. Analysts expect that Sarepta Therapeutic will post $-3.17 EPS for the current fiscal year.
Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of both rare and infectious diseases.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.